Monoclonal antibody (mAb) product innovation aim of facility expansion in KansasAugust 23, 2024A $130-million investment through 2026 is expected to bolster production and development of monoclonal antibody-based therapy, including a potential product in canine dermatology.
SPONSORED CONTENTThe clear reco for hidden stressOur therapeutic nutrition targets underlying stress in cats with GI or urinary issues — helping provide relief to pets and their humans. + Learn More